Karus Therapeutics is aiming to make the treatment of inflammatory diseases and cancer more effective through the development of best-in-class small-molecule drugs that target epigenetic mechanisms and lipid kinase signalling pathways.

The outstanding potency, efficacy and excellent tolerability of Karus’s HDAC inhibitors (HDI) represent a unique and innovative approach to this important drug target and brings the promise of a new gold-standard in the treatment of rheumatoid arthritis, psoriasis and cancer.

Karus’s lipid kinase signalling programme brings together a world-class research and development team that are using new insights to the design and development of innovative drugs to treat inflammatory disease and cancer.